Asparaginase Panel-994

Test info

  
Asparaginase Panel
  
994
  
LAB994
  
MSO
  
Pegaspargase
PEG-asparaginase
PEG-L-asparaginase
Asparlas
Oncaspar
Erwinaze
L-Asparaginase
Rylaze
  

Used to monitor Asparaginase therapy for sufficient enzyme activity, to assess silent inactivation by patient sensitization (activity assay). To assess if a patient is producing antibodies against asparaginase (antibody assay).

  

Measurement of samples are made against a standard curve generated from E. coli L‐asparaginase with each run. Calculations for Erwinaze®, Oncaspar®, Asparlas, and Rylaze® were empirically derived and utilize a correction factor that has been correlated to the E. coli L‐asparaginase activity.

Specimen

  
Serum
  
  
2 mL
  
0.5 mL
  

Immediately following collection, mix sample by gently inverting 5 times

  
  1. Allow sample to clot for a minimum of 30 minutes
  2. Spin within two (2) hours of sample collection
  3. Transfer serum to a False bottom plasma/serum transport vial/tube (AHL), labelled as serum
  
  

Immediately following collection, mix sample by gently inverting 5 times

  
  1. Allow sample to clot for a minimum of 30 minutes
  2. Spin within two (2) hours of sample collection
  3. Transfer serum to a false bottom plasma/serum transport vial/tube (AHL), labelled as serum
  
  

Indicate date and time of last injection on Granger Genetics Requistion

  

Frozen (preferred) - 30 days

Refrigerated - 3 days

Ambient - 1 day

Freeze/Thaw Cycles: 3

  

Gross hemolysis, lipemia or icterus

Performance

  
Granger Genetics Lab
  

Spectrophotometry/absorbance-based enzyme‐coupled kinetic reaction

Traditional antigen-capture ELISA assay

Clinical and Interpretive info

  

None. Physician established therapeutic range.

Billing

  
82657 (activity enzyme)
83516 (antibody assay)
  • 82657 x 4 (If the drug administered is not specified then results will be reported for Oncaspar, Erwinaze, Asparlas, and Rylaze)

Tracking

  
03/16/2023
  
05/22/2023
  
03/17/2023